Kamada Ltd. (KMDA)
| Market Cap | 302.44M |
| Revenue (ttm) | 127.19M |
| Net Income (ttm) | 22.25M |
| Shares Out | 40.30M |
| EPS (ttm) | 0.48 |
| PE Ratio | 14.02 |
| Forward PE | 714.29 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $6.73 |
| Previous Close | $6.81 |
| Change ($) | -0.08 |
| Change (%) | -1.17% |
| Day's Open | 6.84 |
| Day's Range | 6.73 - 6.89 |
| Day's Volume | 74,214 |
| 52-Week Range | 4.56 - 11.73 |
Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pa...
REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition...
Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.
Kamada Ltd. (KMDA) CEO Amir London on Q3 2020 Results - Earnings Call Transcript
Kamada (KMDA) delivered earnings and revenue surprises of 100.00% and 5.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Kamada (NASDAQ:KMDA) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share rose 7.14% over the past year to $0.15, which beat the estimate of $0.06.
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the t...
We believe Kamada looks cheap, as there are long-tailed asset returns from the Takeda deal which the market may be overlooking. Recent retraction in Kamada's shares on the charts signals a pot...
The biotech specializes in plasma-derived protein therapeutics.
REHOVOT, Israel, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has signed an agreement with the Israe...
REHOVOT, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions wit...
Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.
Kamada Ltd. (NASDAQ: KMDA) took a big step in the fight against COVID-19 on Tuesday when the biopharmaceutical company announced initial interim results from its ongoing midstage coronavirus s...
REHOVOT, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced the completion of enrollment and initial in...
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Convalescent plasma holds promise for treating COVID-19, but it's still unproven.
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the ...
REHOVOT, Israel and FORT LEE, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA) and Kedrion Biopharma, two leading biopharmaceutical companies specialized in plasma-d...
Kamada's (KMDA) CEO Amir London on Q2 2020 Results - Earnings Call Transcript
Kamada (KMDA) delivered earnings and revenue surprises of -25.00% and -4.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced changes to the composition of its B...
Shares of Kamada (NASDAQ:KMDA) moved lower by 2.5% in pre-market trading after the company reported Q2 results.
REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and ...
On Wednesday, August 12, Kamada (NASDAQ: KMDA) will release its latest earnings report.
REHOVOT, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that the first patient has been recruited to...
REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.
Kamada might be the least well-known biotech company working on a COVID-19 treatment right now.
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety
Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
REHOVOT, Israel, June 17, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today provided an update on its development of a pla...
Kamada (KMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kamada Ltd (KMDA) CEO Amir London on Q1 2020 Results - Earnings Call Transcript
Kamada (KMDA) delivered earnings and revenue surprises of 62.50% and 8.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Kamada (NASDAQ:KMDA) were flat in pre-market trading after the company reported Q1 results.
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
REHOVOT, Israel, March 11, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial-stage plasma-derived biopharmaceutical company, today provided an update on progress relat...
REHOVOT, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form ...
Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada’s Growth Plans and Execution of Strategic Business Opportunities Execut...
Kamada (KMDA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
REHOVOT, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomize...
REHOVOT, Israel, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a bindin...
REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical ...
Kamada Ltd. (KMDA) CEO Amir London on Q3 2019 Results - Earnings Call Transcript
Kamada (KMDA) delivered earnings and revenue surprises of 66.67% and 14.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB ® in 2017
About KMDA
Kamada develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and sna... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1990 |
| CEO Amir London | Employees 429 |
| Stock Exchange NASDAQ | Ticker Symbol KMDA |
Financial Performance
In 2019, Kamada's revenue was $127.19 million, an increase of 11.11% compared to the previous year's $114.47 million. Earnings were $22.25 million, a decrease of -0.20%.
Analyst Forecasts
According to 3 analysts, the average rating for Kamada stock is "Strong Buy." The 12-month stock price forecast is 11.00, which is an increase of 63.45% from the latest price.